Jan O.
- Country
- Norway
- Department
- Oncology
Research Overview
- Phase 3 Randomized Double-Blind Study of Talazoparib and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
- Outcome-Adaptive Randomized Multi-Arm Study of Radium-223 Dichloride, Abiraterone Acetate, and Drug Combinations in Metastatic Prostate Cancer Patients
- C5731001 - An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)
Data & Insights
Has run more than one trial at 83 of 249 partner sites.
Specializations
Urological Oncology
Specialized in treating advanced forms of urothelial carcinoma and muscle-invasive bladder cancer, with particular emphasis on novel therapeutic combinations and immunotherapy approaches.
- Bladder Cancer Therapeutics
- Urothelial Cancer Management
- Immunotherapy Integration
Focuses on developing treatment strategies for both localized and metastatic disease states.
Kidney Cancer Research
Conducts innovative research in advanced renal cell carcinoma and clear cell renal cancer, exploring targeted therapies and immune-based treatment approaches.
- Renal Cell Carcinoma Treatment
- Novel Therapeutic Combinations
- First-line Treatment Strategies
Specializes in developing therapeutic solutions for advanced kidney cancer patients.
Prostate Cancer Treatment
Expert in treating metastatic castration-resistant prostate cancer, investigating combination therapies and targeted treatment approaches.
- Advanced Prostate Cancer Management
- Combination Therapy Development
- Treatment Resistance Studies
Focuses on innovative therapeutic strategies for advanced prostate cancer cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.